- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Avalyn Pharma Takes a Breath to Raise $300M in IPO Cash for Lung Drug Trials | 1 | MedCity News | ||
| Do | Lung disease drug developer Avalyn surges on public debut | 1 | Seeking Alpha | ||
| Do | Börsengang von Avalyn Pharma: Hohe Überzeichnung und konzentrierte Zuteilung | 2 | Investing.com Deutsch | ||
| Do | Avalyn seeks $300m from its IPO | 1 | pharmaphorum | ||
| Do | Pulmonary fibrosis biotech Avalyn Pharma prices upsized IPO at $18, the high end of the range | 1 | Renaissance Capital | ||
| AVALYN PHARMA Aktie jetzt für 0€ handeln | |||||
| Do | Avalyn heads to Nasdaq with oversized $300M IPO to fund reformulated respiratory drugs | 1 | FierceBiotech | ||
| Do | Avalyn Pharma prices $300M IPO at $18 per share | 1 | Seeking Alpha | ||
| Do | Avalyn Pharma Prices Upsized $300 Mln IPO At $18 Per Share | 343 | AFX News | WASHINGTON (dpa-AFX) - Avalyn Pharma Inc. (AVLN), a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering of 16.67 million shares at a price... ► Artikel lesen | |
| Do | Avalyn Pharma Inc.: Avalyn Announces Pricing of Upsized Initial Public Offering | 98 | GlobeNewswire (Europe) | BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) ("Avalyn"), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm... ► Artikel lesen | |
| Do | Avalyn Pharma prices upsized IPO at $18 per share | 2 | Investing.com | ||
| Mi | Pulmonary fibrosis biotech Avalyn Pharma increases shares offered by 41% ahead of $283 million IPO | 4 | Renaissance Capital | ||
| Mo | Avalyn Pharma Inc. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 24.04. | Avalyn aims for $182M IPO to fund phase 3 trials of reformulated respiratory drugs | 1 | FierceBiotech | ||
| 23.04. | Pulmonary fibrosis biotech Avalyn Pharma sets terms for $201 million IPO | 1 | Renaissance Capital | ||
| 23.04. | Avalyn Pharma Inc. - S-1/A, General form for registration of securities | - | SEC Filings | ||
| 10.04. | Inhaled drug developer Avalyn files for U.S. IPO | 3 | Seeking Alpha | ||
| 09.04. | Chasing a tough-to-treat lung disease, Avalyn plans an IPO | 2 | BioPharma Dive | ||
| 09.04. | Pulmonary fibrosis drug developer Avalyn files IPO | 3 | pharmaphorum | ||
| 09.04. | Avalyn plans IPO to fund phase 3 trials of inhaled versions of approved respiratory drugs | 2 | FierceBiotech | ||
| 09.04. | Pulmonary fibrosis biotech Avalyn Pharma files for a $100 million IPO | 3 | Renaissance Capital |
1 2 Weiter >>
23 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 29,035 | +1,84 % | QIAGEN bremst Erwartungen: QuantiFERON schwächelt, Hoffnung auf zweites Halbjahr | QIAGEN startet schwach ins Jahr: Umsatz stagniert, QuantiFERON belastet - Prognose gesenkt, Hoffnung liegt auf stärkerem zweiten Halbjahr. Der Diagnostik- und Life-Sciences-Konzern QIAGEN ist verhalten... ► Artikel lesen | |
| BIONTECH | 88,20 | +1,38 % | BioNTech vor Wendepunkt: Diese Zahlen entscheiden jetzt | BioNTech steht nach dem Rückgang des Corona-Geschäfts vor einem strategischen Umbruch und richtet seinen Fokus zunehmend auf die Onkologie. Investoren blicken gespannt auf kommende Quartalszahlen und... ► Artikel lesen | |
| EVOTEC | 5,240 | +4,70 % | Evotec-Aktie vor Schicksalszone: Durchbruch oder Absturz? | © Foto: fn SymbolbildEvotec hat zuletzt für Aufsehen gesorgt. Innerhalb weniger Wochen kletterte die Aktie um fast 50 Prozent nach oben, doch jetzt nähert sie sich einer Marke, die über vieles entscheiden... ► Artikel lesen | |
| ERASCA | 10,640 | +17,18 % | Erasca, Inc.: Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors | Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L... ► Artikel lesen | |
| TANGO THERAPEUTICS | 21,530 | -2,40 % | Stifel raises Tango Therapeutics stock price target on drug combo potential | ||
| INHIBRX BIOSCIENCES | 129,02 | +3,17 % | Morning Market Movers: Axe Compute, Inhibrx Biosciences, Huachen AI Parking Management Technology, 1-800-FLOWERS.COM See Big Swings | OTTAWA (dpa-AFX) - At 9:00 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,470 | 0,00 % | Summit Therapeutics leads all large-cap healthcare stocks in YoY CapEx growth | ||
| ABSCI | 4,985 | +5,84 % | H.C. Wainwright reiterates Absci stock rating on hair loss data | ||
| RECURSION PHARMACEUTICALS | 3,465 | +4,68 % | Recursion Expands Strategic Partnership with Citeline to Advance Its AI-Enabled ClinTech Platform | NEW YORK and SALT LAKE CITY, March 31, 2026 (GLOBE NEWSWIRE) -- Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 41,210 | -2,74 % | Enliven Therapeutics, Inc.: Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones | Cumulative major molecular response (MMR) rate of 69% by 24 weeks, with 53% of patients achieving MMR by 24 weeks in ongoing randomized Phase 1b cohorts
ELVN-001... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 63,66 | +4,91 % | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026 | ||
| OSR HOLDINGS | 0,703 | 0,00 % | OSR Holdings, Inc.: OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 | OSR Holdings to Present VXM01 Licensing Agreement at Emerging Growth Conference May 7, 2026 BELLEVUE, WA / ACCESS Newswire / April 30, 2026 / OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare holding... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 11,150 | -5,43 % | Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update | ~1.35 million total VOQUEZNA prescriptions filled to date$58.3 million in Q1 net revenues, a 104% increase year-over-yearQ1 operating expenses of $61.8 million; non-GAAP operating expenses of $56.2... ► Artikel lesen | |
| VERADERMICS | 98,77 | -7,89 % | Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01 | ||
| MODERNA | 39,200 | +0,11 % | Moderna (MRNA): 10 Best Performing S&P 500 Stocks So Far in 2026 |
AVALYN PHARMA INC gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AVALYN PHARMA INC finden Sie auf Wallstreet Online.